Carriers of the APOE E4 allele have an increased risk of developing Alzheimer's disease. However, it is less clear whether APOE E4 status may also be involved in non-pathological cognitive ageing. The present study investigated the associations between APOE genotypes and cognitive change over 8 years in older community-dwelling individuals. APOE genotype was determined in 501 participants of the Lothian Birth Cohort 1921, whose intelligence had been measured in childhood in the Scottish Mental Survey 1932. A polymorphic variant of TOMM40 (rs10524523) was included to differentiate between the effects of the APOE E3 and E4 allelic variants. Cognitive performance on the domains of verbal memory, abstract reasoning and verbal fluency was assessed at mean age 79 years (n = 501), and again at mean ages of 83 (n = 284) and 87 (n = 187). Using linear mixed models adjusted for demographic variables, vascular risk factors and IQ at age 11 years, possession of the APOE E4 allele was associated with a higher relative rate of cognitive decline over the subsequent 8 years for verbal memory and abstract reasoning. Individuals with the long allelic variant of TOMM40, which is linked to APOE E4, showed similar results. Verbal fluency was not affected by APOE E4 status. APOE E2 status was not associated with change in cognitive performance over 8 years. In nondemented older individuals, possession of the APOE E4 allele predicted a higher rate of cognitive decline on tests of verbal memory and abstract reasoning between 79 and 87 years. Thus, possession of the APOE E4 allele may not only predispose to Alzheimer's disease, but also appears to be a risk factor for non-pathological decline in verbal memory and abstract reasoning in the ninth decade of life.
Introduction
Possession of the apolipoprotein E (APOE) E4 allele is a well-established risk factor for Alzheimer's disease. 1 It has been implicated in both the age of onset 2 and the rate of cognitive decline associated with this disease. 3 The lipid transport protein APOE is encoded by the polymorphic APOE gene, which has three allelic variants, E2, E3 and E4. Whereas the APOE2 protein may exert a protective effect from Alzheimer's disease, 4 the APOE4 isoform has been related to reduced neuronal survival and cognitive impairment. 5, 6 Although individuals carrying at least one copy of the APOE E4 allele have an increased risk of developing Alzheimer's disease, it is less clear whether the APOE genotype may also be involved in non-pathological cognitive ageing: several studies indicate that possession of the APOE E4 allele relates to increased cognitive decline during normal ageing, [7] [8] [9] [10] [11] [12] [13] [14] but other studies do not find evidence for such an association. [15] [16] [17] [18] Various explanations for these conflicting results may be put forward. First, cross-sectional studies assessing interindividual differences in the level of cognitive performance may yield results that differ from those obtained in studies examining the change of cognitive performance within individuals over time. Only longitudinal studies are able to determine definitely whether possession of the APOE E4 allele is associated with within-person cognitive changes. However, such studies have not unequivocally offered support for the possible involvement of APOE E4 carrier status in age-related cognitive decline. [7] [8] [9] 12, 14, 18, 19 Second, in light of the involvement of the APOE E4 allele in Alzheimer's disease, it is important to exclude from the study participants with possible dementia, in order to avoid overestimating the association between APOE E4 status and non-pathological age-related cognitive decline. Failing to exclude cases of incipient dementia, particularly at follow-up, was an important limitation of some of the above-mentioned longitudinal studies. 8, 12 Third, although APOE E4 status might differentially affect various cognitive functions, such as episodic memory and executive functioning, 20, 21 some studies only focused on general cognitive ability rather than assessing a range of specific cognitive domains. 12, 18 Furthermore, few of the earlier studies have controlled for previous cognitive ability, which may confound the relationship between APOE E4 allele status and age-related cognitive decline, as childhood mental ability accounts for about 50% of the variance associated with cognitive ability in adulthood. 22 Thus, even in old age, the level of cognitive function tested is a combination of at least three things: the level of the longstanding stable trait of intelligence, any age-related change that has taken place and error of measurement. Finally, although vascular risk factors, such as hypertension, diabetes and smoking, are associated with APOE genotype as well as cognitive performance, 23 ,24 few of the above-mentioned studies correct for these potential confounders.
None of these earlier studies have taken into account the possible influence of the translocase of the outer mitochondrial membrane 40 homolog (TOMM40) variable-length polymorphism (rs10524523) on the relationship between APOE allele status and cognitive performance in old age. The TOMM40 gene, which encodes an essential mitochondrial protein, is adjacent to and in linkage disequilibrium with APOE. 25 The TOMM40 polymorphism is characterized by a variable number of T residues (poly-T repeat) that may be categorized into 'short' ( < 20T residues), 'long' (X20T residues) or 'very long' (X30T residues). 26 Linkage with APOE is such that the APOE E4 allele is almost always linked to a long poly-T repeat, whereas the APOE E3 allele is linked to either a short or a very long poly-T repeat. 27 Relevant to the present study, longer TOMM40 poly-T repeats have been associated with an earlier onset of Alzheimer's disease. 27 It has been suggested that the risk of Alzheimer's disease in APOE E3 carriers with a very long TOMM40 poly-T repeat might equal, or even exceed, the risk generally associated with the APOE E4 allele. 26 It is not known whether the TOMM40 poly-T variants might also have a role in nonpathological cognitive decline. Therefore, it is important to consider both APOE E4 carrier status and TOMM40 poly-T repeat status when assessing agerelated cognitive decline in older individuals.
Previously, we investigated the influence of APOE E4 allele status on cognitive performance in a nondemented sample of older community-dwelling individuals, the Lothian Birth Cohort 1921. 10, 11 In cross-sectional analyses, we found that possession of the APOE E4 allele was associated with lower verbal memory performance at age 79 years. 11 However, verbal fluency and abstract reasoning were not affected by APOE E4 carrier status. 11 In addition, by assessing cognitive performance across the lifecourse, we demonstrated that the APOE E4 allele significantly predicted cognitive change from childhood to old age. 10 The present study was undertaken to extend further our previous research by investigating the longitudinal associations between APOE genotypes and cognitive change from mean age 79 years to mean age 87 in participants of the Lothian Birth Cohort 1921. We attempted to compensate for the above-mentioned limitations accompanying earlier research, by using a longitudinal design, excluding cases of possible dementia at baseline as well as at follow-up, assessing different domains of cognitive functioning, and correcting the analyses for previous mental ability as well as a large number of potential confounders. In addition, we analyzed the effects of the TOMM40 poly-T polymorphism, to assess whether linkage with TOMM40 might influence the relationship between APOE E3 or E4 carrier status and cognitive performance. Moreover, by using a narrow age cohort, any problems associated with heterogeneity of APOE's effect on cognitive function at different ages were excluded.
Subjects and methods

Study population
The study population was the Lothian Birth Cohort 1921. This cohort consists of 550 surviving participants of the Scottish Mental Survey 1932, which tested cognitive ability in almost all children born in 1921 and attending school in Scotland in June 1932. 28 Participants living in the Edinburgh area were recruited for medical and cognitive retesting via general practitioner's patient lists and advertisements in the media, as described elsewhere. 22, 29 All participants who had completed the initial reassessments at mean age 79 years (old age baseline), excluding those who had withdrawn or were known to have died, were invited to take part in the followup measurements at mean ages of 83 (n = 454, of whom 335 agreed to participate) and 87 years (n = 268). Of the participants invited, 321 were tested at age 83, and 207 at age 87. Reasons for not attending included withdrawal (n = 16 at age 83; n = 4 at age 87), inability or refusal to participate (n = 80 at age 83; n = 42 at age 87), having moved away (n = 13 at age 83; n = 4 at age 87), exclusion due to dementia or memory problems (n = 3 at age 87) and death (n = 10 at age 83; n = 8 at age 87). 30, 31 Of the total sample of 550 individuals, 229 had died during the course of the study. All participants lived independently in the community at baseline and most were in good general health.
At baseline, five participants reported a history of dementia-related illness, and nine individuals scored < 24 on the Mini-Mental State Examination (MMSE), 32 which may suggest possible dementia. These individuals were excluded from statistical analysis, along with participants who maintained contact with the study and developed symptoms of dementia during the follow-up period (n = 27). APOE genotyping was successful for all but six of the participants with valid cognitive data at baseline (n = 507). The resulting study sample consisted of 501 individuals (204 men, 297 women) at age 79 years, 284 individuals (123 men, 161 women) at age 83 and 187 individuals (82 men, 105 women) at age 87.
Cognitive tests
The MMSE 32 was used as a brief screening test for possible dementia. The maximum score is 30. An overall score < 24 was considered an indication of possible cognitive pathology. In the Scottish Mental Survey 1932, the Moray House Test no 12 was administered as a measure of general cognitive ability at age 11 years. 28 This test consists of 75 items, has a maximum score of 76, and has to be completed within 45 min. Raw test scores were corrected for age in days at the time of testing and converted to IQ-type scores (mean = 100, s.d. = 15).
At each wave of testing in old age, a battery of cognitive tests was administered to assess important cognitive domains. The Verbal Fluency test 33 provides a measure of executive functioning. Participants are required to name as many words as possible beginning with the letter C in 1 min. This process is repeated for the letters F and L. The overall test score is the total number of correct words named. Verbal declarative memory was assessed by means of the Logical Memory subtest from the Wechsler Memory Scale-Revised. 34 Two short stories, each containing 25 memory items, are read aloud. Immediate recall, as well as delayed recall after about 25 min, are recorded. The total score, which has a maximum of 100, is the sum of the two immediate and two delayed recall scores. Raven's Standard Progressive Matrices 35 was used to measure abstract reasoning. The test consists of sixty items, each presenting a pattern that needs to be completed. The outcome measure used here is the total number of items correctly completed within 20 min.
Genotyping
Genomic DNA was isolated from venous blood. APOE genotype was determined by PCR amplification of a 227-bp fragment of the APOE gene containing two polymorphic sites that account for the three alleles, E2, E3, and E4, 36 followed by restriction digest with Cfo1, and electrophoresis in 4% NuSieve gel.
The TOMM40 poly-T variant (rs10524523) was genotyped by Polymorphic DNA Technologies (Alameda, CA, USA) using PCR amplification of the target sequence followed by automated Sanger sequencing. The method exploits the fact that fluorescence-based Sanger sequencing reactions introduce an extra fluorescent 'A' residue on fully extended primerextension products. Rather than directly analyzing the poly-T region, the pattern of these terminal Apeaks in the sequencing electropherogram was used to determine the lengths of the various alleles present. Two independent assays: 'assay 1' and 'assay 2' were used. To achieve a high level of specific amplification, a two-step, nested PCR strategy to amplify the region flanking the length polymorphism was used. The primers used in assay 1 for these amplifications were as follows:
The primers used in assay 2 for these amplifications were as follows:
The first 'outer' PCR was performed in a 384-well plate by combining in each well B10 ng of genomic DNA with one unit of Klen Taq (Ab Peptides, Inc, St Louis, MO, USA), 0.5 ml of 10 Â PCR buffer, 1.0 ml of 5.0 M betaine, 0.175 ml dimethyl sulfoxide, 0.8 ml of a mixture of dNTPs (2.5 mM each), 2 mM of each of the two outer oligonucleotide primers plus water to bring the entire reaction volume per well to a total of 5.0 ml. The second 'inner' PCR was performed in a 384-well plate by combining in each well 0.8 ml of the product from the first PCR with 0.25 units of Klen Taq, 0.5 ml of 10 Â PCR buffer, 1.0 ml of 5.0 M betaine, 0.175 ml dimethyl sulfoxide, 0.2 ml of a mixture of dNTPs (2.5 mM each), 2 mM of each of the two inner oligonucleotide primers (2 mM each), plus water to bring the entire reaction volume per well to a total of 5.0 ml. PCR conditions for both reactions were 40 cycles of 94 1C for 20 s, 55 1C for 25 s and 72 1C for 60 s. The 'inner' PCR products were then purified using PCR Cleanup Plates (MultiScreen384 PCR, Millipore Corp, Billerica, MA, USA), with a final elution of each sample using 16 ml of water. An internal standard was added to each amplified sample product before running of the Sanger sequencing reactions. Using the mixed template described above, fluorescent Sanger sequencing reactions were performed using the forward 'inner' PCR primer as a sequencing primer. Reactions were carried out in a 384-well plate using 0.8 ml of the PCR product described above with 0.125 ml Big Dye Mix (Applied BioSystems, Inc, Carlsbad, CA, USA), 0.215 ml 5Â Dilution Buffer (Applied BioSystems, Inc), 0.25 ml of a 1 mM solution of the forward 'inner' primer, 0.105 ml dimethyl sulfoxide, 0.6 ml of 5 M betaine, plus water to bring the entire volume to 3.0 ml. Plates were then placed in a thermocycler and subjected to 30 cycles of the following conditions: 96 1C for 10 s, 50 1C for 15 s and 60 1C for 120 s. Sequencing reactions were analyzed on a 3730XL DNA Analyzer (Applied BioSystems, Inc). TOMM40 poly-T data were available for 498 participants.
Lifestyle and health-related variables Body mass index (BMI, kg m À2 ), smoking status (yes/ no), and alcohol consumption (standard units per week) were recorded at age 79. Total serum cholesterol (mmol l À1 ) was determined in venous blood samples at age 79. Self-reported history of cardiovascular disease (yes/no), cerebrovascular disease (yes/ no), hypertension (yes/no) and diabetes (yes/no) were recorded at age 79, and again at ages 83 and 87.
Statistical analysis
Normality of data distributions was ascertained by visual inspection of normal P-P plots. APOE genotype was defined and coded as E4 þ or E4À, depending on the presence of at least one E4 allele, which is consistent with many other studies investigating the effect of APOE E4 status on cognitive functioning. 20, 21 The TOMM40 allelic variants were classified into three categories, according to the length of the poly-T repeat, that is, 'short' ( < 20T residues), 'long' (X20T residues) or 'very long' (X30T residues).
The longitudinal associations between APOE E4 status and cognitive performance were assessed by means of linear mixed models. 37 This analytical method takes into account the intraindividual correlation between repeated measurements and allows the inclusion of participants with incomplete data at follow-up. Akaike's information criterion indicated that an unstructured covariance structure best fit the data. Separate models were fitted for APOE E4 allele status in relation to each of the three dependent cognitive variables, that is, verbal fluency, logical memory and Raven's matrices. The longitudinal effect of APOE E4 allele status on cognitive functions was estimated by the two-way interaction between time (measured in years since baseline, that is, 0, 4 and 8 years, which is acceptable because there is very little age variation among the participants within each wave) and APOE E4 allele status, which represents the rate of change in cognitive performance as a function of APOE E4 carrier status. The statistical models were adjusted for a number of covariates in three consecutive steps. First, the analyses were corrected for the demographic variables age (in days), age 2 (to test for non-linear effects of age) and sex (model 1). Age was centered around the mean to reduce the correlation between the terms for age and age 2 . In model 2, the analyses were additionally adjusted for age 11 IQ to reduce the confounding effect of previous cognitive ability on age-related change in cognitive performance. Finally, smoking status, alcohol consumption, body mass index, total serum cholesterol, history of cardiovascular disease, history of cerebrovascular disease, history of hypertension and history of diabetes were entered (model 3), to correct for potential confounding by vascular risk factors. 23, 24 This procedure was repeated with MMSE score as the dependent variable, to examine the effect of APOE E4 allele status on general cognitive performance on this widely-used clinical test. Linear mixed models with APOE E2 allele status (coded as presence or absence of at least one E2 allele) as the independent variable were used to examine the effect of the APOE E2 allele on age-related cognitive change.
The relationship between the TOMM40 poly-T polymorphism and cognitive performance was analyzed for the two cognitive domains showing significant associations with APOE E4 carrier status, that is, verbal memory and abstract reasoning. First, to explore the overall effect of TOMM40 genotype on cognitive performance, summary measures for the 8-year change in logical memory and Raven's matrices were calculated, by regressing test score at mean age 87 on test score at mean age 79 and saving the residuals. Univariate analysis of variance and independent samples t-tests were used to assess whether cognitive change differed according to TOMM40 genotype.
Second, linear mixed models were performed to investigate further the cross-sectional and longitudinal associations between TOMM40 genotype and cognitive performance, while correcting for demographic and health-related variables. Separate models were fitted for TOMM40 genotype in relation to logical memory and Raven's matrices. The analyses were repeated in APOE E4 non-carriers, APOE E3E4 heterozygotes, and APOE E3E3 homozygotes, to differentiate between the effects of the APOE E3 and E4-linked TOMM40 variants.
Statistical differences were considered significant at P-values < 0.05. All analyses were performed using SPSS 16.0 for Apple Macintosh (SPSS Inc., Chicago, IL, USA). Table 1 shows the baseline characteristics of the participants according to APOE E4 carrier status. Allele frequencies in the sample were E2 = 0.10, E3 = 0.77 and E4 = 0.14. A w 2 -test indicated that APOE was in Hardy-Weinberg equilibrium (P = 0.300). At baseline, distribution of APOE genotypes was as follows: E2E2, n = 2 (0.4%); E2E3, n = 76 (15.2%); E2E4, n = 19 (3.8%); E3E3, n = 292 (58.3%); E3E4, n = 107 (21.4%); and E4E4, n = 5 (1.0%). These genotype frequencies are comparable to those reported in other population-based samples of nondemented older individuals. 12, 14, 19 The covariates did not differ between APOE E4 carriers and non-carriers, except for alcohol consumption, which was lower in APOE E4 carriers, and total serum cholesterol, which was higher in APOE E4 carriers (Table 1 ). In addition, carriers of the APOE E4 allele performed worse on the logical memory test at age 87 (Table 2) .
Results
Descriptives
At baseline, TOMM40 genotypes were distributed as follows: short-short, n = 90 (18.1%); short-long, n = 60 (12.0%); short-very long, n = 178 (35.7%); long-long, n = 5 (1.0%); long-very long, n = 65 (13.1%); and very long-very long, n = 100 (20.1%). Supplementary Table 1 shows the distribution of TOMM40 genotypes stratified by APOE genotype.
Of the 501 participants at baseline, 187 completed the third wave of cognitive testing at mean age 87. Distribution of APOE genotypes at mean age 87 was as follows: E2E2, n = 1 (0.5%); E2E3, n = 27 (14.4%); E2E4, n = 5 (2.7%); E3E3, n = 118 (63.1%); E3E4, n = 35 (18.7%); and E4E4, n = 1 (0.5%). Dropout equaled 69% in APOE E4 carriers, and 61% in noncarriers of the E4 allele (P = 0.115 using a w 2 -test). Logistic regression analysis revealed that dropout was not associated with APOE E4 status (P = 0.098 for dropout due to any reason; P = 0.105 for dropout because of death). However, lower cognitive scores at baseline significantly predicted dropout at follow-up (P < 0.01 for each of the three cognitive measures). w 2 -tests indicated that participants who were lost to follow-up did not differ from the remaining participants in terms of demographic or health-related characteristics, except for smoking, which significantly increased the likelihood of dropping out (P = 0.024).
Associations between APOE E4 and E2 allele status and cognitive performance Table 3 shows the results of the linear mixed model analyses. Significant interactions between APOE E4 allele status and time were identified for logical memory and Raven's matrices, but not for verbal fluency. Possession of the APOE E4 allele was accompanied by an additional annual decline of 0.5 points on the logical memory test, and 0.3 points on Raven's matrices-corresponding to a 4.0 points (0. When the analyses were repeated with MMSE score as the dependent variable, no significant longitudinal effect of APOE E4 allele status was found (estimate (95% CI) for APOE E4 Â time in the fully adjusted model = À0.02 (À0.09; 0.04), P = 0.453). However, APOE E4 carriers showed a significantly greater longitudinal decline in MMSE performance when participants with suspected dementia (MMSE < 24) at mean ages of 83 or 87 (n = 27) were included in the statistical analyses. This association was significant after correction for the demographic variables (estimate (95% CI) for APOE E4 Â time = À0.10 (À0.18; À0.02), P = 0.015), but not after additional correction for age 11 IQ and vascular risk factors (estimate (95% CI) for APOE E4 Â time = À0.05 (À0.13; 0.03), P = 0.193).
Linear mixed models with APOE E2 carrier status as the independent variable did not reveal any significant longitudinal effects on cognitive performance (Supplementary Table 2 ).
Associations between TOMM40 genotype and cognitive performance Supplementary Table 3 shows the cognitive change of participants who completed three waves of testing between mean ages of 79 and 87, categorized according to APOE and TOMM40 genotype. Overall, cognitive change did not vary according to TOMM40 genotype (P = 0.062 for logical memory and P = 0.269 for Raven's matrices). However, when carriers of at least one long poly-T repeat (n = 41) were compared and sex; model 2 is additionally corrected for age 11 IQ and model 3 is additionally corrected for body mass index, alcohol consumption, smoking, total serum cholesterol, history of cardiovascular disease, history of cerebrovascular disease, history of hypertension and history of diabetes. b The estimate for APOE E4 status represents the cross-sectional association between APOE E4 status and cognitive performance at baseline. The time estimate equals the effect of time on cognitive performance in non-carriers of the APOE E4 allele. The estimate for the interaction effect between time and APOE E4 status corresponds to the additional annual change in APOE E4 carriers as compared with non-carriers.
with non-carriers, the 8-year change in logical memory was significantly lower in participants in possession of a long TOMM40 poly-T allele (mean ± s.d. = À4.18 ± 1.12 as compared with 1.06 ± 1.05, P = 0.006).
Linear mixed models, corrected for demographic and health-related variables, did not reveal any significant cross-sectional associations between TOMM40 genotype and Raven's matrices (Table 4) . Logical memory showed a significant cross-sectional relationship with TOMM40 genotype, with statistically significant parameter estimates for TOMM40 variants characterized by at least one long poly-T repeat ( Table 4 ), indicating that logical memory performance at baseline was lower in carriers of the long allelic variant of TOMM40 as compared with non-carriers. No overall longitudinal effects of TOMM40 genotype on logical memory or Raven's matrices were identified; however, the parameter estimates for the long-very long genotype were statistically significant for both cognitive domains ( Table 4 ), implying that this TOMM40 variant was associated with a greater annual decline in logical memory and Raven's matrices. Repeating the analyses with TOMM40 genotype as a dummy variable (1 = presence of at least one long poly-T allele; 0 = no long poly-T allele) revealed a significant cross-sectional association with logical memory performance (parameter estimate (95% CI) = À4.09 (À6.79; À1.39), P = 0.003), and significant longitudinal associations with both logical memory (parameter estimate (95% CI) = À0.52 (À0.95; À0.09), P = 0.019) and Raven's matrices (parameter estimate (95% CI) = À0.26 (À0.51; À0.01), P = 0.040). These results indicate that carriers of the long TOMM40 poly-T allele showed a lower verbal memory performance at baseline, and a greater annual decline on the cognitive domains of verbal memory and abstract reasoning, as compared with non-carriers.
When the analyses were repeated in APOE E4 noncarriers (n = 367), that is, representing only the shortshort, short-very long and very long-very long TOMM40 variants, no significant results were obtained (data not shown). In addition, repeating the analyses in APOE E3E4 heterozygotes with either the shortlong or long-very long TOMM40 genotype (n = 105) did not yield any significant results (data not shown). Repeating the analyses in participants with the APOE E3E3 genotype (n = 290), to differentiate between the APOE E3-linked short and very long TOMM40 allelic variants in individuals without the 'protective' APOE E2 allele or the 'risk' allele APOE E4, did not reveal any significant results (data not shown).
Discussion
We found that APOE E4 allele carrier status was associated with an increased rate of cognitive decline between 79 and 87 years on the domains of verbal memory and abstract reasoning in a narrow age cohort of older community-dwelling individuals. In addition, we found that the long allelic variant of the TOMM40 poly-T polymorphism, which is linked to , sex, age 11 IQ, body mass index, alcohol consumption, smoking, total serum cholesterol, history of cardiovascular disease, history of cerebrovascular disease, history of hypertension and history of diabetes. b The estimates for TOMM40 genotype represent the cross-sectional associations between TOMM40 variants and cognitive performance at baseline, with the TOMM40 short-short genotype as reference category. The time estimate equals the effect of time on cognitive performance in individuals with the TOMM40 short-short genotype. The estimate for the interaction effect between time and TOMM40 genotype corresponds to the additional annual change in cognitive performance associated with TOMM40.
the APOE E4 allele, showed a similar relationship with cognitive performance over 8 years.
Not only did our findings indicate that APOE E4 carrier status may account for a significant proportion of variance associated with cognitive changes in old age, they also suggest that the influence of APOE E4 allele status on age-related cognitive decline may be restricted to specific domains of cognitive functioning, as we did not find any support for an effect of the E4 allele on verbal fluency, which assesses an aspect of executive functioning.
The present results are in agreement with some of those reported by other population-based studies, indicating that APOE E4 allele status may have a negative impact on age-related change in memory performance [7] [8] [9] 11, 14, 19 and abstract reasoning 8 in older individuals. The finding that verbal fluency was not affected by APOE E4 allele status, is in agreement with several other reports, which have put forward that the APOE E4 allele may differentially affect cognitive functioning on various domains. 7, 11, 14, 19 Indeed, the existing literature seems to suggest that the APOE E4 allele may primarily affect episodic memory, although not all studies have found significant effects. 15, 16 Some population-based studies have found that possession of the APOE E4 allele may be associated with decreased general cognitive functioning, 8, 12, 23 but others did not find any evidence for such an association. [17] [18] [19] The fact that the APOE E4 allele showed no association with MMSE score in our study might be due to the relative insensitivity of this test to individual variation in normal cognitive functioning, as it was originally developed to screen for symptoms of cognitive impairment, 32 and has a ceiling effect in the present sample. Not surprisingly, we did find a significant relationship between APOE E4 allele status and MMSE performance when cases of possible dementia at follow-up were included in our study sample, which confirms the notion that the APOE E4 allele may have a role in pathological degrees of cognitive impairment.
We have previously shown that possession of the APOE E2 allele predicted higher verbal memory performance at age 79. 11 However, the present study did not suggest any effect of APOE E2 allele status on the rate of cognitive decline in healthy ageing individuals from 79 to 87 years, suggesting that the beneficial influence of the APOE E2 allele on cognitive functioning may be restricted to individual differences in the level of cognitive performance.
Previous research addressing the relationship between APOE and cognitive functioning has primarily focused on the effects of the 'risk' allele E4 and the 'protective' allele E2. However, recent studies have suggested that the APOE E3 allele, when connected to a very long TOMM40 poly-T repeat, is associated with an earlier onset of Alzheimer's disease, comparable to the age of onset typically observed in APOE E4 carriers. 27 The present study assessed whether the APOE E3 and E4-linked TOMM40 variants might also have a role in non-pathological cognitive decline. Our results did not offer support for an interaction between APOE and TOMM40 in mediating age-related cognitive decline in the ninth decade. We found that only the long TOMM40 allelic variant, which is linked to the APOE E4 allele, was predictive of the rate of cognitive change in old age. Although these findings strengthen our conclusion that APOE E4 carrier status may increase cognitive decline in older individuals, it does not offer support for a separate effect of TOMM40 in relation to non-pathological cognitive functioning. In fact, as other TOMM40 variants were not associated with individual variation in cognitive performance, TOMM40 poly-T status might be considered a marker for APOE E4 carrier status rather than an independent risk factor for cognitive decline in the ninth decade.
APOE E4 carriers might be more susceptible to neurodegeneration than non-carriers due to poor neuronal repair and an elevated risk of atherosclerosis. 5, 6 Indeed, APOE E4 carrier status has been related to increased hippocampal atrophy 38 and a greater decline in cerebral blood flow in frontal, temporal and parietal areas. 39 As the frontal and parietal areas in the brain have been implicated in abstract reasoning, 40 and reduced hippocampal volumes have been associated with memory decline in the ageing population, 41, 42 it may not be unreasonable to assume that the lower performance on memory and reasoning tests observed in APOE E4 carriers might be accounted for by changes in brain morphology. Furthermore, the putative role of APOE E4 in neuronal damage and atherosclerosis might offer a suitable explanation for the finding that APOE E4 carrier status is associated with cognitive performance in old age, but not in childhood 10, 11 or in adults before age 50, 9 as neurodegenerative processes might not take place until later in life.
The aim of our study was to investigate the relationship between APOE genotypes and nonpathological cognitive decline. As APOE E4 carriers are more prone to develop dementia than noncarriers, 1 a potential limitation of population-based studies addressing the effects of the APOE E4 allele on cognitive ageing is that their results might be biased by the possible inclusion of cases of incipient dementia. However, in the present study, all participants lived independently at baseline, had no history of dementia, and obtained MMSE scores of 24 or more at baseline and at follow-up. Therefore, we consider it unlikely that the observed associations are substantially accounted for by incipient dementia.
A possible disadvantage of excluding all individuals with potential dementia at any point is that it may increase survivor bias, which is very common in longitudinal studies performed in older populations. In our study, dropout was associated with a lower level of cognitive functioning at baseline. By using a statistical approach that allows for the inclusion of participants with incomplete data at follow-up, this selection bias was, at least partly, compensated for.
However, if anything selective dropout or exclusion of cognitively impaired participants probably would have caused the observed associations to be underestimated.
Learning effects on cognitive tests may also result in conservative estimates of the longitudinal associations between APOE E4 allele status and cognitive performance, by obscuring possible age-related cognitive decline. In contrast to verbal fluency and abstract reasoning, which declined over 8 years of follow-up, logical memory performance did not show a significant decline between 79 and 87 years, which may be due to procedural learning. Thus, it is conceivable that the observed associations between APOE E4 allele status and verbal memory might have been underestimated.
Another potential source of bias in longitudinal studies is selective attrition. Statistical testing revealed that dropout was not related to APOE E4 carrier status in the present study. Moreover, APOE allele frequencies in our study were similar to those reported for younger populations, 7, 43 which strongly argues against the possibility of selective attrition. The finding that APOE E4 status was not associated with increased dropout or increased mortality in the present study allowed us to compare our results with those obtained in studies performed in younger individuals 7, 8 or study populations with a broader age range, 12, 19 in which comparable genotype distributions were reported.
The strengths of our study were its longitudinal design, the administration of sensitive, domainspecific cognitive tests, the narrow range of chronological age and the adjustment for demographic and lifestyle variables, as well as vascular risk factors. Furthermore, correcting our analyses for childhood intelligence allowed for the assessment of individual variation in cognitive decline in old age, while eliminating the confounding influence of the stable trait of general cognitive ability. 22 Moreover, our study was the first to investigate the potential influence of the TOMM40 poly-T polymorphism on the relationship between APOE allele status and age-related cognitive decline. Finally, the study included three waves of testing spanning most of the ninth decade, and genetic-cognitive examination of this important part of old age is rare.
In conclusion, by using a unique narrow age cohort of initially healthy older individuals, we were able to demonstrate that individual variation in age-related cognitive change in the rarely-studied ninth decade of the human lifecourse was related to APOE E4 allele status. Compared with non-carriers, carriers of the APOE E4 allele showed a greater 8-year decline on the cognitive domains of verbal memory and abstract reasoning. Thus, the E4 allelic variant of the APOE gene may not only predispose to dementia, but may also have a negative impact on cognitive decline in non-demented older individuals. Future studies may further unravel the genetic and environmental determinants of non-pathological cognitive ageing, by addressing the potential mechanisms underlying the association between APOE genotypes and cognitive performance, as well as investigating the potential interactions between the APOE gene and other risk factors.
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